Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Mahendra Singh

Internal Medicine Henderson, NV Medical Doctor

NPI 1063587855 CMS profile 93967

100 N Green Valley Pkwy, Ste. 110, Henderson, NV 89074

Open in the dashboard

General payments

$3,995

235 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Mahendra Singh of Henderson, NV is reported in the CMS Open Payments database as having received $3,995 across 235 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $866 49
2022 General $1,079 63
2021 General $1,116 67
2020 General $473 29
2019 General $461 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mahendra Singh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mahendra Singh were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mahendra Singh Internal Medicine median Middle half National median
2019 $461 $159 $48–$570 $163
2020 $473 $119 $33–$402 $114
2021 $1,116 $135 $37–$521 $132
2022 $1,079 $141 $42–$496 $149
2023 $866 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $870 52 payments
  2. AbbVie, Inc. $490 30 payments
  3. Pfizer Inc. $376 23 payments
  4. Novo Nordisk Inc $341 18 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $293 16 payments
  6. Merck Sharp & Dohme Corporation $194 11 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $117 8 payments
  8. Allergan Inc. $106 6 payments
  9. Biohaven Pharmaceuticals, Inc. $96 6 payments
  10. Dexcom, Inc. $91 6 payments
  11. Other $1,021 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,995 235 payments
Products named General payments · program years 2019–2023
  1. FARXIGA $545 34 payments
  2. BREZTRI $289 16 payments
  3. JARDIANCE $227 13 payments
  4. NURTEC ODT Primary Care $213 14 payments
  5. Ozempic $207 11 payments
  6. PAXLOVID $187 12 payments
  7. UBRELVY $175 12 payments
  8. JANUVIA $159 9 payments
  9. NURTEC ODT Pain $154 10 payments
  10. ELIQUIS $149 9 payments
  11. Other $3,102 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

7,122

Median for Internal Medicine: 777

Drug cost

$404,863

Median for Internal Medicine: $73,373

Branded share of claims

14.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 68 $86,472
Jardiance Empagliflozin Brand 52 $60,334
Mounjaro Tirzepatide Brand 27 $30,083
Ozempic Semaglutide Brand 23 $29,177
Januvia Sitagliptin Phosphate Brand 31 $25,410
Creon Lipase/Protease/Amylase Brand 11 $21,589
Linzess Linaclotide Brand 16 $12,330
Trulicity Dulaglutide Brand 12 $11,290
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $10,732
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 12 $9,856

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$16,345

Medicare's payments for the services billed

Medicare patients

116

Average age 76

Services billed

233

69 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 39%
Chronic kidney disease 36%
Ischemic heart disease 33%
Atrial fibrillation 19%
COPD 19%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record